FDA

Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

Finfeed Archived May 26, 2021

Creso Pharma's target acquisition group Halucenex has entered into an agreement with consultancy group, HetereoGeneity

Noxopharm receives FDA green light to progress towards Veyonda® trial

Finfeed Archived May 19, 2020

Noxopharm has received advice from the FDA to submit Veyonda® for clinical trial in patients infected with COVID-19

G Medical continues expansion, receiving TGA approval for GMP

Finfeed Archived May 05, 2020

G Medical receives Therapeutics Goods Administration (TGA) approval for its G Medical Extended Holter Patch (GMP)

Non-elective treatment profile provides Avita Medical with income stability

Finfeed Archived Apr 08, 2020

AVITA Medical Limited (ASX: AVH) is a med-tech stock worth targeting outside the blue chips such as ResMed, CSL and Ramsay Health Care.

Genetic Signatures builds on SARS technology

Finfeed Archived Mar 30, 2020

Shares in Genetic Signatures Limited (ASX: GSS) were up 50% at one stage on Monday morning as management announced that the company had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-2), the virus that causes COVID-19.

Fda

Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

Noxopharm receives FDA green light to progress towards Veyonda® trial

G Medical continues expansion, receiving TGA approval for GMP

Non-elective treatment profile provides Avita Medical with income stability

Genetic Signatures builds on SARS technology